Answers are grounded in this paper and cite their sources.
Background/Objectives: Tattoo-associated inflammatory reactions during BRAF/MEK inhibitor therapy are uncommon and remain poorly characterized. Building on the case previously reported by Baratta et al., we describe two additional patients with melanoma who developed granulomatous reactions confined to pre-existing tattoos during combined BRAF/MEK inhibition. Case Presentation: Both patients were young men with advanced melanoma and developed well-demarcated eczematous and infiltrated plaques restricted to black tattooed skin. Histological examination showed non-necrotizing granulomatous dermatitis with pigment-containing histiocytes and multinucleated giant cells, consistent with a foreign-body-type reaction. In one patient the reaction remained limited to the skin, whereas the other developed systemic symptoms together with persistent laboratory abnormalities. In both scenarios 18F-FDG PET/CT also showed focal hypermetabolic activity corresponding to the tattooed areas. Conclusions: These observations add to the limited clinical experience with tattoo-restricted granulomatous reactions during BRAF/MEK inhibition. They also underline the broader immunomodulatory effects of targeted therapy and the need to recognize this uncommon adverse event in order to avoid misinterpretation and potentially unnecessary treatment changes. Further reports are needed to better define its pathogenesis and possible association with systemic toxicity or treatment response.
No takes yet. Share an insight, caveat, or question.
Coppolelli et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: